Home
  >  
Section 5
  >  
Chapter 4,252

Novel inhalational murine model of invasive pulmonary aspergillosis

Sheppard, D.C.; Rieg, G.; Chiang, L.Y.; Filler, S.G.; Edwards, J.E.; Ibrahim, A.S.

Antimicrobial Agents and ChemoTherapy 48(5): 1908-1911

2004

ISSN/ISBN: 0066-4804
PMID: 15105158
DOI: 10.1128/aac.48.5.1908-1911.2004
Accession: 004251182
Download citation:  
Text
  |  
BibTeX
  |  
RIS
We developed a novel model of invasive aspergillosis (IA) that recapitulates human disease. Mice were immunosuppressed with cyclophosphamide and cortisone acetate and then infected in an aerosol chamber. This procedure reproducibly delivered 1x103 to 3x103 conidia to the lungs. Lethal pulmonary IA developed over 2 weeks and was prevented by amphotericin B.

Full Text Article emailed within 0-6 h: $19.90




Related References

Natesan, S.K.; L. Cutright, J. 2019: In vivo Efficacy of Posaconazole (POS) against Voriconazole Resistant (VCZ-R) Aspergillus flavus in an Inhalational Neutropenic Murine Model of Invasive Pulmonary Aspergillosis Microbiology Research Journal International: 1-7
Ahmad, S.; Al-Shaikh, A.A.; Khan, Z. 2014: Development of a novel inhalational model of invasive pulmonary aspergillosis in rats and comparative evaluation of three biomarkers for its diagnosis Plos one 9(6): E100524
Steinbach, W.J.; Benjamin, D.K.; Trasi, S.A.; Miller, J.L.; Schell, W.A.; Zaas, A.K.; Foster, W.Michael.; Perfect, J.R. 2004: Value of an inhalational model of invasive aspergillosis Medical Mycology 42(5): 417-425
Sheppard, D.C.; Graybill, J.R.; Najvar, L.K.; Chiang, L.Y.; Doedt, T.; Kirkpatrick, W.R.; Bocanegra, R.; Vallor, A.C.; Patterson, T.F.; Filler, S.G. 2006: Standardization of an experimental murine model of invasive pulmonary aspergillosis Antimicrobial Agents and ChemoTherapy 50(10): 3501-3503
Chiang, L.Y.; Ejzykowicz, D.E.; Tian, Z.-Q.; Katz, L.; Filler, S.G. 2006: Efficacy of ambruticin analogs in a murine model of invasive pulmonary aspergillosis Antimicrobial Agents and ChemoTherapy 50(10): 3464-3466
Szigeti, Z.M.; Talas, L.; Palicz, Z.; Szentesi, P.; Hargitai, Z.; Csernoch, L.; Balla, J.; Pocsi, I.; Banfalvi, G.; Szeman-Nagy, G. 2018: Murine model to follow hyphal development in invasive pulmonary aspergillosis Applied Microbiology and Biotechnology 102(6): 2817-2825
Clemons, K.V.; Schwartz, J.A.; Stevens, D.A. 2011: Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis Medical Mycology 49(8): 834-847
Grahl, N.; Kowalski, C.H.; Cramer, R.A. 2021: Detection of Low Oxygen Microenvironments in a Murine Model of Invasive Pulmonary Aspergillosis Using Pimonidazole Methods in Molecular Biology 2260: 197-205
Madan, T.; Kishore, U.; Singh, M.; Strong, P.; Hussain, E.M.; Reid, K.B.; Sarma, P.U. 2001: Protective role of lung surfactant protein D in a murine model of invasive pulmonary aspergillosis Infection and Immunity 69(4): 2728-2731
Mondon, P.; De Champs, C.; Donadille, A.; Ambroise-Thomas, P.; Grillot, R. 1996: Variation in virulence of Aspergillus fumigatus strains in a murine model of invasive pulmonary aspergillosis Journal of Medical Microbiology 45(3): 186-191
Bhattacharya, S.; Amarsaikhan, N.; Maupin, A.J.; Schlosser, A.; Füchtbauer, E.-M.; Holmskov, U.; Moeller, J.B.; Templeton, S.P. 2021: FIBCD1 Deficiency Decreases Disease Severity in a Murine Model of Invasive Pulmonary Aspergillosis Immunohorizons 5(12): 983-993
Kaur, S.; Gupta, V.K.; Thiel, S.; Sarma, P.U.; Madan, T. 2007: Protective role of mannan-binding lectin in a murine model of invasive pulmonary aspergillosis Clinical and Experimental Immunology 148(2): 382-389
Nawada, R.; Amitani, R.; Tanaka, E.; Niimi, A.; Suzuki, K.; Murayama, T.; Kuze, F. 1996: Murine model of invasive pulmonary aspergillosis following an earlier stage, noninvasive Aspergillus infection Journal of Clinical Microbiology 34(6): 1433-1439
Wiederhold, N.P.; Kontoyiannis, D.P.; Chi, J.; Prince, R.A.; Tam, V.H.; Lewis, R.E. 2004: Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity Journal of Infectious Diseases 190(8): 1464-1471
Peng, Y.; Zhang, H.; Xu, M.; Tan, M-Wah. 2018: A Tet-Off gene expression system for validation of antifungal drug targets in a murine invasive pulmonary aspergillosis model Scientific Reports 8(1): 443
Hartigan, A.J.; Westwick, J.; Jarai, G.; Hogaboam, C.M. 2009: CCR7 deficiency on dendritic cells enhances fungal clearance in a murine model of pulmonary invasive aspergillosis Journal of Immunology 183(8): 5171-5179
Wiederhold, N.P.; Najvar, L.K.; Vallor, A.C.; Kirkpatrick, W.R.; Bocanegra, R.; Molina, D.; Olivo, M.; Graybill, J.R.; Patterson, T.F. 2008: Assessment of serum (1->3)-beta-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis Antimicrobial Agents and ChemoTherapy 52(3): 1176-1178
Wiederhold, N.P.; Tam, V.H.; Chi, J.; Prince, R.A.; Kontoyiannis, D.P.; Lewis, R.E. 2006: Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis Antimicrobial Agents and ChemoTherapy 50(2): 469-473
Lewis, R.E.; Prince, R.A.; Chi, J.; Kontoyiannis, D.P. 2002: Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis Antimicrobial Agents and Chemotherapy 46(10): 3208-3214
Lewis, R.E.; Albert, N.D.; Kontoyiannis, D.P. 2008: Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis Antimicrobial Agents and ChemoTherapy 52(11): 4178-4180